Immutep Limited
IMMP
Last
$3.55
Day
-7.6%
1y
-89.8%
5y
-94.8%
52w
-94.6%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
5.09
EMA 50
6.32
EMA 200
16.27
20d high
-45.0%
5y high
-96.2%
5y range
0th
Positions held
Your positionsIMMP isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$4.44
Stop
$3.34
Stop distance
5.9%
Target vs last
+25.1%
Fundamentals
| Market cap | $28.30M | Enterprise value | -$39.53M | Trailing P/E | — | Forward P/E | -0.74 |
| PEG | — | Price / book | 0.65 | Beta | 2.30 | Dividend yield | 0.00% |
| Revenue growth | 6.3% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -2.6% |
| Profit margin | 0.0% | ROE | -77.3% | ROA | -42.5% | Debt / equity | 0.02 |
| Current ratio | 5.69 | Free cash flow | -$36.99M | Analyst recommendation | none | Mean target | $30.00 |
| 52w high | $70.60 | 52w low | $3.80 |
Quarterly
No data yet.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $14.6M | — | $0.0M | $0.0M | $0.2M |
| Op margin | -560.5% | — | — | — | -19861.2% |
| Net income | -$79.3M | — | -$42.7M | -$39.9M | -$32.2M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$81.6M | — | -$46.6M | -$41.4M | -$33.8M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Immutep Receives ~A$0.86 Million R&D Tax Incentive
2026-09-21 · Change to American Depositary Share Ratio
2026-09-11 · Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
2026-07-30 · Immutep Quarterly Activities Report Q4 FY26
2026-07-14 · Immutep Granted New US Patent for Cancer Treatment Methods
2026-07-14 · Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
Price (daily)
Full chart · RSI · MACD · patternsIMMP · daily-32.2% over 13 sessions
Close EMA21 EMA50 EMA200